Roche enters into definitive merger agreement to acquire Spark Therapeutics

Roche and Spark Therapeutics, Inc. today announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-cash transaction.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news